GlassScriptPhysician profile
Nicholas Flebotte
NPI 1598318610
$8,529.96
in general payments reported to CMS, 2019-2025
21 companies · $461 in 2025
The $461 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $95.59 · 2021: $737 · 2022: $1,455 · 2023: $2,017 · 2024: $3,220 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,666 · Travel and Lodging: $2,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,666.31 |
| Travel and Lodging | $2,031.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,639.15 | 2022-2025 | Hydrus Microstent, Precision 1, Dailies Total1 |
| Biotissue Holdings INC. | $1,748.22 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $1,378.61 | 2022-2025 | Infuse, Lotemax Sm, Vyzulta |
| Allergan, INC. | $592.13 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $494.13 | 2019-2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $250.13 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $230.74 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $198.72 | 2021 | |
| Abbvie INC. | $182.28 | 2023 | |
| Coopervision INC. | $171.80 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $114.22 | 2022-2023 | Acthar |
| Ivantis, INC | $87.35 | 2019 | |
| Carl Zeiss Meditec, INC. | $86.67 | 2019 | |
| Lkc Technologies, INC. | $71.44 | 2022 | |
| Horizon Therapeutics Plc | $67.32 | 2022-2023 | Tepezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $60.69 | 2021-2025 | Opd-III |
| Rxsight INC | $54.70 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Glaukos Corporation | $36.90 | 2019 | |
| Dompe US, INC. | $32.21 | 2021-2022 | |
| Alimera Sciences, INC. | $17.55 | 2020 | |
| Thea Pharma INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Flebotte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.